se ha leído el artículo
array:19 [ "pii" => "X0211699500025690" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:35" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2656 "formatos" => array:3 [ "EPUB" => 164 "HTML" => 2139 "PDF" => 353 ] ] "itemSiguiente" => array:15 [ "pii" => "X0211699500025682" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:36" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3777 "formatos" => array:3 [ "EPUB" => 170 "HTML" => 3220 "PDF" => 387 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "«ASPECTOS ACTUALES DEL CONTROL DE LA PRESIÓN ARTERIAL» Epidemiología de la hipertensión arterial y situación actual del control de presión en España" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "36" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. COCA" "autores" => array:1 [ 0 => array:1 [ "nombre" => "A. COCA" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025682?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025682/v0_201502091333/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699500025705" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2000-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2000;20 Supl 1:34" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2398 "formatos" => array:3 [ "EPUB" => 158 "HTML" => 1949 "PDF" => 291 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Riesgo cardiovascular en diabetes y nefropatía" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "34" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. ROMERO" "autores" => array:1 [ 0 => array:1 [ "nombre" => "R. ROMERO" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025705?idApp=UINPBA000064" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025705/v0_201502091333/es/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Alpha-blockers in the Treatment of Hypertension" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "35" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. KAPLAN" "autores" => array:1 [ 0 => array:1 [ "nombre" => "M. KAPLAN" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 Alpha-blockers in the Treatment of Hypertension M. Kaplan University of Texas Southwestern. Medical Center at Dallas. Selective alpha1-blockers act as vasodilators, both on arteries and veins. The specificity for alpha-adrenoreceptors induces relaxation of vascular smooth muscle with little reflex stimulation of cardiac output because catecholamine release is modulated via nonblocked alpha-receptors. As a result, peripheral resistance falls during rest and during various cardiovascular stresses, while cardiac output remains unchanged or slightly increased and cardiovascular reflex-control mechanisms are well maintained. These favorable haemodynamic effects have been demonstrated during exercise, when they particularly contrast with the effects of beta-adrenergic receptor blockers, which are often poorly tolerated by athletes. The various selective alpha1-blockers differ from each other according to their pharmacokinetic and pharmacodynamic properties. These properties have been examined for prazosin, the first and for over 10 years the only member of this class available; terazosin, introduced in 1987, and doxazosin, which became available in 1991. Terazosin and doxazosin are less lipid soluble and have half or less of the affinity for alpha1-receptors than does prazosin. For these and other reasons, they induce a less rapid and less profound initial fall in blood pressure, particularly after standing, than does prazosin. These may translate into differences in the propensity for first-dose and subsequent hypotensive symptoms and certainly provides for a longer duration of action for the second-generation alpha1-blockers. More recently, a controlled-release doxazosin gastrointestinal therapeutic system (GITS) have been developed. This GITS system in an osmotic pump that slowly releases the active drug so that peak levels are achieved 10 to 12 hours after oral intake. The plasma drug concentration declines more gradually for the doxazosin GITS formulation than the stan- dard doxazosin tablet, providing high blood levels even at the end of 24 hours. These long-acting alpha-blockers have been found to lower both systolic and diastolic blood pressure by approximately 10 mm Hg in multiple groups of patients with mild-to-moderate hypertension. In a multicentre trial, doxazosin was equally effective in patients over the age of 65 years and in younger patients, as well as in both black and nonblack patients. In double-blind randomized parallel group comparisons made between the newly marketed doxazosin GITS formulation and the standard doxazosin tablets, doxazosin GITS was well tolerated and fewer patients on the GITS formulation discontinued therapy because of side effects and syncope was not seen with the GITS preparation. Unfortunately, alpha-blockers have not been included in the multiple randomized placebo-controlled trials performed over the past 30 years that have proved the ability of antihypertensive therapy to reduce cardiovascular morbidity and mortality. The situation is in process of changing. In particular, the massive Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which will be completed in 2003, is comparing the ability of a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril) and an alpha-blocker (doxazosin) with a diuretic to reduce cardiovascular mortality and morbidity in almost 45,000 high-risk hypertensives. In the meantime, alpha-blockers are widely recommended for the initial choice of therapy in hypertensives with one or more comorbid conditions, including dyslipidaemia, diabetes and prostatism. BIBLIOGRAFÍA 1. Kaplan NM: Chapter 7: Treatment of hypertension: Drug Therapy in Clinical Hypertension 7th ed. Williams and Wilkins, 1998. 2. Os I and Stokke HP: Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovascular Pharmacology 33: 791-797, 1999. Correspondence: Norman M., Kaplan M. D. University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd. Dallas, TX 75235-8899 35 " "pdfFichero" => "P7-E170-S140-A1885.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/main.assets" "Apartado" => array:4 [ "identificador" => "35407" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Suplementos" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/P7-E170-S140-A1885.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025690?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 10 | 12 | 22 |
2024 Octubre | 57 | 71 | 128 |
2024 Septiembre | 71 | 42 | 113 |
2024 Agosto | 96 | 67 | 163 |
2024 Julio | 76 | 80 | 156 |
2024 Junio | 70 | 69 | 139 |
2024 Mayo | 115 | 96 | 211 |
2024 Abril | 78 | 37 | 115 |
2024 Marzo | 69 | 44 | 113 |
2024 Febrero | 71 | 53 | 124 |
2024 Enero | 57 | 35 | 92 |
2023 Diciembre | 65 | 38 | 103 |
2023 Noviembre | 85 | 57 | 142 |
2023 Octubre | 83 | 38 | 121 |
2023 Septiembre | 60 | 24 | 84 |
2023 Agosto | 82 | 31 | 113 |
2023 Julio | 85 | 46 | 131 |
2023 Junio | 97 | 32 | 129 |
2023 Mayo | 83 | 30 | 113 |
2023 Abril | 43 | 23 | 66 |
2023 Marzo | 71 | 30 | 101 |
2023 Febrero | 59 | 29 | 88 |
2023 Enero | 67 | 33 | 100 |
2022 Diciembre | 48 | 26 | 74 |
2022 Noviembre | 68 | 42 | 110 |
2022 Octubre | 56 | 42 | 98 |
2022 Septiembre | 35 | 28 | 63 |
2022 Agosto | 45 | 36 | 81 |
2022 Julio | 44 | 35 | 79 |
2022 Junio | 75 | 40 | 115 |
2022 Mayo | 53 | 29 | 82 |
2022 Abril | 50 | 43 | 93 |
2022 Marzo | 36 | 41 | 77 |
2022 Febrero | 100 | 42 | 142 |
2022 Enero | 123 | 30 | 153 |
2021 Diciembre | 143 | 47 | 190 |
2021 Noviembre | 95 | 39 | 134 |
2021 Octubre | 72 | 41 | 113 |
2021 Septiembre | 75 | 44 | 119 |
2021 Agosto | 75 | 38 | 113 |
2021 Julio | 65 | 50 | 115 |
2021 Junio | 82 | 19 | 101 |
2021 Mayo | 117 | 38 | 155 |
2021 Abril | 206 | 59 | 265 |
2021 Marzo | 161 | 14 | 175 |
2021 Febrero | 165 | 21 | 186 |
2021 Enero | 90 | 21 | 111 |
2020 Diciembre | 93 | 29 | 122 |
2020 Noviembre | 86 | 10 | 96 |
2020 Octubre | 73 | 7 | 80 |
2020 Septiembre | 49 | 8 | 57 |
2020 Agosto | 64 | 16 | 80 |
2020 Julio | 88 | 21 | 109 |
2020 Junio | 100 | 27 | 127 |
2020 Mayo | 84 | 20 | 104 |
2020 Abril | 84 | 16 | 100 |
2020 Marzo | 112 | 18 | 130 |
2020 Febrero | 114 | 19 | 133 |
2020 Enero | 127 | 23 | 150 |
2019 Diciembre | 78 | 18 | 96 |
2019 Noviembre | 70 | 13 | 83 |
2019 Octubre | 78 | 14 | 92 |
2019 Septiembre | 109 | 21 | 130 |
2019 Agosto | 54 | 12 | 66 |
2019 Julio | 46 | 13 | 59 |
2019 Junio | 38 | 15 | 53 |
2019 Mayo | 54 | 7 | 61 |
2019 Abril | 115 | 24 | 139 |
2019 Marzo | 47 | 10 | 57 |
2019 Febrero | 27 | 16 | 43 |
2019 Enero | 21 | 16 | 37 |
2018 Diciembre | 38 | 18 | 56 |
2018 Noviembre | 32 | 8 | 40 |
2018 Octubre | 40 | 12 | 52 |
2018 Septiembre | 37 | 8 | 45 |
2018 Agosto | 21 | 7 | 28 |
2018 Julio | 24 | 8 | 32 |
2018 Junio | 13 | 5 | 18 |
2018 Mayo | 14 | 7 | 21 |
2018 Abril | 22 | 3 | 25 |
2018 Marzo | 10 | 4 | 14 |
2018 Febrero | 14 | 6 | 20 |
2018 Enero | 8 | 2 | 10 |
2017 Diciembre | 22 | 4 | 26 |
2017 Noviembre | 9 | 5 | 14 |
2017 Octubre | 13 | 3 | 16 |
2017 Septiembre | 5 | 4 | 9 |
2017 Agosto | 23 | 9 | 32 |
2017 Julio | 16 | 4 | 20 |
2017 Junio | 22 | 6 | 28 |
2017 Mayo | 14 | 2 | 16 |
2017 Abril | 10 | 1 | 11 |
2017 Marzo | 17 | 1 | 18 |
2017 Febrero | 11 | 1 | 12 |
2017 Enero | 6 | 1 | 7 |
2016 Diciembre | 9 | 2 | 11 |
2016 Noviembre | 29 | 1 | 30 |
2016 Octubre | 47 | 4 | 51 |
2016 Septiembre | 41 | 2 | 43 |
2016 Agosto | 69 | 0 | 69 |
2016 Julio | 104 | 6 | 110 |
2016 Junio | 90 | 0 | 90 |
2016 Mayo | 78 | 0 | 78 |
2016 Abril | 30 | 0 | 30 |
2016 Marzo | 27 | 0 | 27 |
2016 Febrero | 33 | 0 | 33 |
2016 Enero | 31 | 0 | 31 |
2015 Diciembre | 34 | 0 | 34 |
2015 Noviembre | 23 | 0 | 23 |
2015 Octubre | 26 | 0 | 26 |
2015 Septiembre | 32 | 0 | 32 |
2015 Agosto | 29 | 0 | 29 |
2015 Julio | 23 | 0 | 23 |
2015 Junio | 8 | 0 | 8 |
2015 Mayo | 14 | 0 | 14 |